CLINICAL RESEARCH: HEART FAILURE
Aldosterone Receptor Antagonism Induces Reverse Remodeling When Added to Angiotensin Receptor Blockade in Chronic Heart Failure
Anna K.Y. Chan, MB, MRCP*,
John E. Sanderson, MD, FRCP, FACC*,*,
Tian Wang, PhD*,
Wynnie Lam, FRCR ,
Gabriel Yip, MD*,
Mei Wang, MD, PhD*,
Yat-Yin Lam, MB, MRCP*,
Yan Zhang, PhD*,
Leata Yeung, RN, MPhil*,
Eugene B. Wu, MD*,
Wilson W.M. Chan, MD*,
John T.H. Wong, MB, MRCP*,
Nina So, FRCR and
Cheuk-Man Yu, MD, FRCP*
* Division of Cardiology, Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong SAR, China
Department of Diagnostic Radiology and Organ Imaging, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong SAR, China.
Manuscript received January 24, 2007;
revised manuscript received March 9, 2007,
accepted March 12, 2007.
* Reprint requests and correspondence: Prof. John E. Sanderson, Department of Cardiovascular Medicine, The Medical School, University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom. (Email: j.e.sanderson{at}bham.ac.uk).
Objectives: The objective of this study was to determine if adding spironolactone to an angiotensin II receptor blocker improves left ventricular (LV) function, mass, and volumes in chronic heart failure.
Background: Add-on spironolactone therapy substantially improves clinical outcomes among patients with severe heart failure (HF) on standard therapy. However, the value of combining spironolactone with an angiotensin II receptor blocker on LV reverse remodeling in mild-to-moderate systolic HF is unclear.
Methods: Fifty-one systolic HF patients with left ventricular ejection fraction (LVEF) <40% were randomly assigned to receive 1-year treatment of candesartan and spironolactone (combination group) or candesartan and placebo (control group). Reverse remodeling was assessed by serial cardiac magnetic resonance imaging and echocardiographic tissue Doppler imaging (TDI).
Results: There were significant improvements in LVEF (35 ± 3% vs. 26 ± 2%, p < 0.01) and reduction of LV end-diastolic volume index (121 ± 16 ml/m2 vs. 155 ± 14 ml/m2, p = 0.001), end-systolic volume index (88 ± 17 ml/m2 vs. 120 ± 15 ml/m2, p < 0.0005), and LV mass index (81 ± 6 g/m2 vs. 93 ± 6 g/m2, p = 0.002) in the combination group at 1 year. In addition, there was significant increase in peak basal systolic velocity and strain by TDI, decrease in index of filling pressure, and increase in cyclic variation integrated backscatter. In the control group, there were no significant changes in all these parameters after 1 year.
Conclusions: The addition of spironolactone to candesartan has significant beneficial effects on LV reverse remodeling in patients with mild-to-moderate chronic systolic HF.
|
Abbreviations and Acronyms
| | ACE = angiotensin-converting enzyme | | ARB = angiotensin II receptor blocker | | CMR = cardiac magnetic resonance imaging | | CVIB = cyclic variation of integrated backscatter | | HF = heart failure | | LV = left ventricle/ventricular | | LVEDVI = left ventricular end-diastolic volume index | | LVEF = left ventricular ejection fraction | | LVESVI = left ventricular end-systolic volume index | | TDI = tissue Doppler imaging |
|
Related Articles
-
Inside This Issue of JACC
J. Am. Coll. Cardiol. 2007 50: A31-A32.
[Full Text]
[PDF]
-
Myocardial Structural Effects of Aldosterone Receptor Antagonism in Heart Failure
- Jay N. Cohn
J. Am. Coll. Cardiol. 2007 50: 597-599.
[Full Text]
[PDF]
This article has been cited by other articles:

|
 |

|
 |
 
D. Y. Leung
Aldosterone Blockade in Metabolic Syndrome: Hitting the Target or Still Missing Some Links?
J. Am. Coll. Cardiol. Img.,
December 1, 2011;
4(12):
1250 - 1252.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. A. Rafael-Fortney, N. S. Chimanji, K. E. Schill, C. D. Martin, J. D. Murray, R. Ganguly, J. E. Stangland, T. Tran, Y. Xu, B. D. Canan, et al.
Early Treatment With Lisinopril and Spironolactone Preserves Cardiac and Skeletal Muscle in Duchenne Muscular Dystrophy Mice
Circulation,
August 2, 2011;
124(5):
582 - 588.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Barsheshet, A. J. Moss, M. Eldar, D. T. Huang, W. J. Hall, H. U. Klein, S. McNitt, J. S. Steinberg, D. J. Wilber, W. Zareba, et al.
Time-dependent benefit of preventive cardiac resynchronization therapy after myocardial infarction
Eur. Heart J.,
July 1, 2011;
32(13):
1614 - 1621.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Guglin, O. Kristof-Kuteyeva, I. Novotorova, and P. Pratap
Aldosterone Antagonists in Heart Failure
Journal of Cardiovascular Pharmacology and Therapeutics,
June 1, 2011;
16(2):
150 - 159.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Verhaert, K. Richards, J. A. Rafael-Fortney, and S. V. Raman
Cardiac Involvement in Patients With Muscular Dystrophies: Magnetic Resonance Imaging Phenotype and Genotypic Considerations
Circ Cardiovasc Imaging,
January 1, 2011;
4(1):
67 - 76.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. S. Broberg, S. S. Chugh, C. Conklin, D. J. Sahn, and M. Jerosch-Herold
Quantification of Diffuse Myocardial Fibrosis and Its Association With Myocardial Dysfunction in Congenital Heart Disease
Circ Cardiovasc Imaging,
November 1, 2010;
3(6):
727 - 734.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Zannad, J. J. V. McMurray, H. Drexler, H. Krum, D. J. van Veldhuisen, K. Swedberg, H. Shi, J. Vincent, and B. Pitt
Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS-HF)
Eur J Heart Fail,
June 1, 2010;
12(6):
617 - 622.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. E. Udelson, A. M. Feldman, B. Greenberg, B. Pitt, R. Mukherjee, H. A. Solomon, and M. A. Konstam
Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Evaluating the Effect of Aldosterone Antagonism With Eplerenone on Ventricular Remodeling in Patients With Mild-to-Moderate Heart Failure and Left Ventricular Systolic Dysfunction
Circ Heart Fail,
May 1, 2010;
3(3):
347 - 353.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. W. K. Yip and J. E. Sanderson
Heart failure with normal ejection fraction
Heart,
May 1, 2010;
96(10):
791 - 791.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. G. Fraser
Echocardiographic epidemiology--an emerging tool for early diagnosis, studying pathophysiology, predicting prognosis, and testing treatments
Eur. Heart J.,
March 2, 2009;
30(6):
642 - 644.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
U. Landmesser, K. C. Wollert, and H. Drexler
Potential novel pharmacological therapies for myocardial remodelling
Cardiovasc Res,
February 15, 2009;
81(3):
519 - 527.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. A. Ezekowitz and F. A. McAlister
Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials
Eur. Heart J.,
February 2, 2009;
30(4):
469 - 477.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
O. M. Gutierrez, H. Tamez, I. Bhan, J. Zazra, M. Tonelli, M. Wolf, J. L. Januzzi, Y. Chang, and R. Thadhani
N-terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) Concentrations in Hemodialysis Patients: Prognostic Value of Baseline and Follow-up Measurements
Clin. Chem.,
August 1, 2008;
54(8):
1339 - 1348.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. N. DeMaria, J. J. Bax, O. Ben-Yehuda, P. Clopton, G. K. Feld, G. S. Ginsburg, B. H. Greenberg, J. D. Knoke, W. Y.W. Lew, J. A.C. Lima, et al.
Highlights of the Year in JACC 2007
J. Am. Coll. Cardiol.,
January 29, 2008;
51(4):
490 - 512.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W.H. W. Tang and G. S. Francis
The Year in Heart Failure
J. Am. Coll. Cardiol.,
December 11, 2007;
50(24):
2344 - 2351.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. N. Cohn
Myocardial Structural Effects of Aldosterone Receptor Antagonism in Heart Failure
J. Am. Coll. Cardiol.,
August 14, 2007;
50(7):
597 - 599.
[Full Text]
[PDF]
|
 |
|
|